Accelerate Diagnostics Sees Prelim. Q4 Sales $3.3M vs $3.92M Est., FY21 Sales $11.8M vs $12.28M Est. - Accelerate Diagnostics (NASDAQ:AXDX) - Benzinga

Accelerate Diagnostics Sees Prelim. Q4 Sales $3.3M vs $3.92M Est., FY21 Sales $11.8M vs $12.28M Est.

AXDXAccelerate Diagnostics Inc

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Benzinga.com on devices